Drug Development

Lonza’s SimpliFiH Services addresses bioavailability challenges with drug substance, solid-state characterization, and drug product for first-in-human studies.

University of Southern California scientists have made an advancement in chimeric antigen receptor (CAR) T-cell therapy that seems to eliminate its severe side effects, making the treatment safer and potentially available in outpatient settings.

EDCTP has granted EUR10 million to a collaboration of African and European antimalarial drug researchers to support late-stage clinical trials of a novel antimalarial combination.

Hovione Technology has acquired global rights to a dry powder inhaler for pulmonary drug delivery, the Papillon DPI invented by Dr. Klaus-Dieter Beller.

Catalent’s acquisition of Paragon Bioservices will provide expertise and in expanding gene and cell therapy markets.

Patient-centric drug development is becoming more important in the bio/pharma industry.

Catalent invests $5 million in hot melt extrusion capabilities at Somerset, NJ facility.

The companies form a strategic joint venture for developing and manufacturing live biotherapeutics.

The acquisition is expected to expand CURE Pharmaceutical’s technology platform in oral drug delivery.

Characterizing particles and understanding bulk powder behavior is critical to get the best pharma product.

Pharmaceutical Technology Europe spoke with Manuel Leal, business development director for Idifarma to learn more about spray drying and how it can support patient-centric drug development.

It is important to address manufacturing problems associated with the shorter shelf-life of pegylated L-asparaginase (pegaspargase) upon long-term storage in the form of a solution.

Confidence in the quality systems and scientific competence of the API manufacturing team is essential.

Better drug design and patient education may promote improved personal and public health.

Easier access to information, targeting smaller patient populations, and increased regulatory focus on patient outcomes are driving patient‑centric drug development.

More work needed to advance drug design and development effectively.

Market demand and regulatory guidance continues to promote improved medication design.

The company has launched a comprehensive portfolio of custom cell biology solutions and a new cell-line engineering technology.

The collaboration will apply artificial intelligence and machine learning to the development of drugs for treating a range of cancers.

Worth up to $605 million, the collaboration will focus on studying a preclinical novel target that could lead to potential new treatments for autoimmune diseases.

PDC*line Pharma has entered into a licensing agreement with LG Chem to develop a lung cancer vaccine in Asia.

Merck KGaA opened a collaborative bio/pharma development facility in Molsheim, France and announced an investment plan through 2025 for its Darmstadt, Germany headquarters.

Think ahead to production requirements when planning strategies in early development of gene and cell therapies.

The guidance provides nonclinical and clinical recommendations to sponsors for the development of products for the prevention of HIV-1 infection.

Alcami Biologics formed to meet market demands for biological drug development services.